Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(11):813-815; doi:10.1093/jnci/djh174
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Carter, H. B.
Right arrow Articles by Isaacs, W. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carter, H. B.
Right arrow Articles by Isaacs, W. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

EDITORIALS

Improved Biomarkers for Prostate Cancer: A Definite Need

H. Ballentine Carter, William B. Isaacs

Affiliation of authors: James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD

Correspondence to: H. Ballentine Carter, MD, James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, 600 N. Wolfe St., Marburg Bldg., Rm. 403, Baltimore, MD 21287 (e-mail: hcarter@jhmi.edu)

The first 10% of the full text of this article appears below.

Prostate-specific antigen (PSA) screening for prostate cancer is now widespread in the United States among men of all ages (1). Although prostate cancer mortality has fallen in the United States since the onset of widespread screening, a relationship between screening and the decline in mortality has not been proven.

There is general agreement among clinicians that the PSA test has the highest predictive value for prostate cancer, that PSA screening can detect early-stage cancers possibly 10 years earlier than without the PSA test, and that most cancers detected . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
L. L. Cheng, M. A. Burns, J. L. Taylor, W. He, E. F. Halpern, W. S. McDougal, and C.-L. Wu
Metabolic Characterization of Human Prostate Cancer with Tissue Magnetic Resonance Spectroscopy
Cancer Res., April 15, 2005; 65(8): 3030 - 3034.
[Abstract] [Full Text] [PDF]